IRIS
DELLA PORTA, MATTEO GIOVANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.051
EU - Europa 903
AS - Asia 312
AF - Africa 164
SA - Sud America 29
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 3
Totale 6.474
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.000
FI - Finlandia 281
CN - Cina 200
IE - Irlanda 198
NG - Nigeria 159
FR - Francia 87
DE - Germania 82
NL - Olanda 61
IT - Italia 50
CA - Canada 49
SE - Svezia 44
GB - Regno Unito 43
IN - India 22
TR - Turchia 21
BR - Brasile 18
BE - Belgio 17
JP - Giappone 16
SG - Singapore 15
AU - Australia 10
ES - Italia 10
IR - Iran 9
HK - Hong Kong 8
RU - Federazione Russa 7
CL - Cile 6
CH - Svizzera 5
IL - Israele 4
ZA - Sudafrica 4
AT - Austria 3
DK - Danimarca 3
NO - Norvegia 3
PH - Filippine 3
BD - Bangladesh 2
EC - Ecuador 2
EU - Europa 2
LA - Repubblica Popolare Democratica del Laos 2
MY - Malesia 2
NZ - Nuova Zelanda 2
SA - Arabia Saudita 2
TH - Thailandia 2
UA - Ucraina 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AR - Argentina 1
BO - Bolivia 1
CZ - Repubblica Ceca 1
GR - Grecia 1
HU - Ungheria 1
ID - Indonesia 1
KR - Corea 1
KZ - Kazakistan 1
MA - Marocco 1
MD - Moldavia 1
MX - Messico 1
PA - Panama 1
PE - Perù 1
PL - Polonia 1
RO - Romania 1
SI - Slovenia 1
VN - Vietnam 1
Totale 6.474
Salva come PNG Salva come JPEG
Città #
Wilmington 1.026
Chandler 954
San Mateo 356
Helsinki 281
Ann Arbor 246
Dublin 197
Boardman 165
Leawood 165
Shanghai 165
Benin City 159
Lawrence 159
Princeton 159
Woodbridge 121
Ashburn 114
Fairfield 101
New York 101
Paris 86
Amsterdam 59
Houston 41
Toronto 36
Seattle 32
London 30
Cambridge 23
Falls Church 23
Norwalk 22
Kocaeli 18
San Diego 18
Brussels 17
Redwood City 17
Los Angeles 15
Monmouth Junction 15
Beijing 14
Tokyo 13
São Paulo 12
Redmond 11
Milan 9
Pune 9
San Francisco 9
Tappahannock 9
Mumbai 6
Abbiategrasso 5
Genoa 5
Phoenix 5
Singapore 5
Des Moines 4
Falkenstein 4
Frankfurt am Main 4
Clearwater 3
Leinfelden-echterdingen 3
Manila 3
Nashville 3
San Jose 3
Urmia 3
Bangkok 2
Barcelona 2
Berlin 2
Bhubaneswar 2
Boulder 2
Canberra 2
Cary 2
Central District 2
Charlotte 2
Chesterfield 2
Hackney 2
Hanover 2
Hefei 2
Huntington 2
Jamaica Plain 2
Johnson City 2
Las Vegas 2
Mandi 2
Melbourne 2
Morbegno 2
Moscow 2
Oslo 2
Pittsburgh 2
Quito 2
Röllbach 2
Sevilla 2
Stockholm 2
Tulsa 2
Vancouver 2
Vienna 2
Vientiane 2
Wuhan 2
Yokohama 2
Alba 1
Almaty 1
Athens 1
Auckland 1
Bellville 1
Bergamo 1
Boston 1
Buccinasco 1
Cagliari 1
Cape Town 1
Central 1
Centurion 1
Chengdu 1
Chisinau 1
Totale 5.143
Salva come PNG Salva come JPEG
Nome #
SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts 180
Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes. Nat Commun. 2015 Jan 9;6:5901. 106
Flow cytometry immunophenotyping for the evaluation of bone marrow dysplasia. 81
Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group 79
Carenza C, Calcaterra F, Oriolo F, Di Vito C, Ubezio M, Della Porta MG, Mavilio D, Della Bella S. 72
Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. 68
Should cytoreductive treatment be performed before transplantation in patients with high-risk myelodysplastic syndrome? 57
CD34 and CD2 expression in acute promyelocytic leukemia. 56
Diagnostic Utility of Flow Cytometry in Myelodysplastic Syndromes. 56
Identification of gene expression-based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes 55
Clinical Effects of Driver Somatic mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With allogeneic Hematopoietic Stem-Cell Transplantation 55
Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms 54
Breast and renal cancer-Derived endothelial colony forming cells share a common gene signature 53
Classification and prognostic evaluation of myelodysplastic syndromes 52
THE IMPACT OF THE DEGREE OF ANEMIA ON SURVIVAL OF PATIENTS WITH MYELODYSPLASTIC SYNDROME. A BASIS FOR PROGNOSTIC ASSESSMENT AND CLINICAL DECISION MAKING 52
Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM) 52
Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes 51
Leukemic transformation of polycythemia vera: a single center study of 23 patients 50
A prognostic model for predicting the impact of comorbidities on survival of patients with myelodysplastic syndromes 50
CD56 as a marker of an ILC1-like population with NK cell properties that is functionally impaired in AML. 49
Dendritic cells in acute promyelocytic leukaemia. 48
Vascular endothelial growth factor overexpression in myelodysplastic syndrome bone marrow cells: biological and clinical implications. 48
Multilineage involvement in the 5q- syndrome: a fluorescent in situ hybridization study on bone marrow smears. 48
Biological and clinical relevance of matrix metalloproteinases 2 and 9 in acute myeloid leukaemias and myelodysplastic syndromes. 48
Hematologic responses with deferasirox therapy in transfusion-dependent myelodysplastic syndromes patients. 48
Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes 48
JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders. Cancer. 2006 Nov 1;107(9):2206-11. PubMed PMID: 16998940. 48
WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). 47
Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. 47
Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes 47
Consolidation treatment with autologous peripheral blood progenitor cell transplantation in acute myeloid leukemia: a single center experience. 47
Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues. 47
Lymphocyte subpopulation and dendritic cell phenotyping during antineoplastic therapy in human solid tumors. 46
Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome. 46
Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes 46
Clinical relevance of extra-hematologic comorbidity in the management of patients with myelodysplastic syndrome. 45
Prognosis of secondary acute myeloid leukemia 45
Myelodysplastic syndromes and bone marrow microenvironment. 45
Clinical evaluation of extra-hematological comorbidity in myelodysplastic syndromes: "ready-to-wear" versus "made-to-measure" tools. 45
Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndrome 45
Clinical relevance of clonal hematopoiesis in persons aged ≥80 years 45
Sequence variations in mitochondrial ferritin: distribution in healthy controls and different types of patients. 44
Prognostic significance of reproducible immunophenotypic markers of marrow dysplasia 44
Methylenetetrahydrofolate reductase C677T and A1298C gene variants in adult non-Hodgkin's lymphoma patients: association with toxicity and survival 44
VASCULAR ENDOTHELIAL GROWTH FACTOR OVEREXPRESSION IN BONE MARROW CELLS FROM PATIENTS WITH MYELODYSPLASTIC SYNDROME: BIOLOGICAL AND CLINICAL RELEVANCE 44
A continuous-time Markov model approach for modeling myelodysplastic syndromes progression from cross-sectional data. 44
Multicentre validation of a reproducible flow cytometric score for the diagnosis of low-risk myelodysplastic syndromes: results of a European LeukemiaNET study. 43
Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance. 43
Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome 43
Simian virus 40 and lymphoproliferative disorder. 43
High resolution melting for the identification of mutations in the iron responsive element of the ferritin light chain gene. 42
Novel trial designs for high-risk myelodysplastic syndromes. 42
Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. 42
Predicting survival and leukemic evolution in patients with myelodysplastic syndrome 42
Clinical and biological implications of driver mutations in myelodysplastic syndromes 42
Burkitt-like lymphoma infiltrating a hyperfunctioning thyroid adenoma and presenting as a hot nodule. 42
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet 42
Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms 42
Thiotepa, Fludarabine, and Busulfan Conditioning Regimen before T Cell-Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia: A Bicentric Experience of 100 Patients. 41
Chronic lymphocytic leukemia with 6q- shows distinct hematological features and intermediate prognosis. 41
Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1 41
Involvement of the region 13q14 in a patient with admantinoma of the long bones 41
Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders 41
Pretransplant active disease status and HLA class II mismatching are associated with increased incidence and severity of cytokine release syndrome after haploidentical transplantation with posttransplant cyclophosphamide 41
Multicenter validation of a simplified method for paroxysmal nocturnal hemoglobinuria screening. 40
CD34+ and endothelial progenitor cells in patients with various degrees of congestive heart failure. 40
Late appearance of the 11q22.3-23.1 deletion involving the ATM locus in B-cell chronic lymphocytic leukemia and related disorders. Clinico-biological significance. 40
Dendritic cell recovery after allogeneic stem-cell transplantation in acute leukemia: correlations with clinical and transplant characteristics. 40
Pretransplantation therapy with hypomethylating agents in patients with myelodysplastic syndromes receiving reduced-intensity conditioning regimens. 40
Differentiation of follicular dendritic sarcoma cells into functional myeloid-dendritic cell-like elements. 40
The role of the iron transporter ABCB7 in refractory anemia with ring sideroblasts. 40
An unusual clinical presentation of multiple myeloma with involvement of the oro-pharynx. 39
Harmonemia: a universal strategy for flow cytometry immunophenotyping-A European LeukemiaNet WP10 study 39
Alterata espressione dei canali del Ca2+ in cellule progenitrici endoteliali di pazienti affetti da carcinoma cellulare renale, mielofibrosi idiopatica e tumore della mammella 39
Cytogenetic study in therapy-related myelodysplastic syndromes (t-MDS) and acute non-lymphocytic leukaemia (t-ANLL). 39
Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study. 39
Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia. 39
Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes. 38
Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study. 38
ANALYSIS OF THE MITOCHONDRIAL FERRITIN PHYSIOPATHOLOGICAL ROLE IN SIDEROBLASTIC ERYTHROPOIESIS 38
The effect of transfusion dependency and secondary iron overload on survival of patients with myelodysplastic syndrome 38
Importance of classical morphology in the diagnosis of myelodysplastic syndrome. 38
Treatment of anemia with erythroid stimulating agents in myelodysplastic syndromes. 37
Myelodysplastic syndromes with bone marrow fibrosis. 37
Clinical Relevance of Clonal Hematopoiesis in the Oldest-Old Population: Analysis of the "Health and Anemia" Study 37
Clinical characteristics and treatment outcome of an 86-year-old patient with acute myeloid leukaemia with acute promyelocytic-like morphology and uncommon RARA fusion variant. 37
Prognostic models in myelodysplastic syndromes 36
Outcome after allogeneic bone marrow transplantation in cytogenetic high-risk myelodysplastic syndromes and acute myeloid leukemia. 36
Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients. 36
Circulating endothelial cell separation from peripheral blood of patients affected by myelodysplastic syndromes: Preliminary results obtained by a new immunomagnetic procedure 36
DHFR 19-bp insertion/deletion polymorphism and MTHFR C677T in adult acute lymphoblastic leukaemia: is the risk reduction due to intracellular folate unbalancing? 36
Use of granulocyte-colony stimulating factor during acute myocardial infarction to enhance bone marrow stem cell mobilization in humans: clinical and angiographic safety profile. 36
Gene expression profiling of CD34+ cells in patients with the 5q- syndrome 35
Clinical importance of interphase cytogenetics detecting occult chromosome lesions in myelodysplastic syndromes with normal karyotype. 35
Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised international prognostic scoring system (IPSS-R) 35
In vitro Cytotoxic Effect of Trabectedin on JMML AND CMML Cell Populations 34
Effects of mitochondrial ferritin overexpression in normal and sideroblastic erythroid progenitors. 34
In patients with myelodysplastic syndromes response to rHuEPO and G-CSF treatment is related to an increase of cytogenetically normal CD34 cells. 34
From cancer patients to cancer survivors: the issue of Cardioncology--a biological perspective. 34
Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts 34
Totale 4.624
Salva come PNG Salva come JPEG
Categoria #
all - tutte 47.618
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 47.618
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20205 0 0 0 0 0 0 0 0 0 0 0 5
2020/20211.835 20 53 99 10 18 531 242 104 360 220 16 162
2021/20221.059 70 12 24 213 23 26 29 132 105 70 323 32
2022/20232.634 374 85 210 325 252 237 5 234 493 210 176 33
2023/20241.039 121 178 278 47 27 115 57 149 20 46 1 0
Totale 6.572